[LOCARDI, Elsa, DINKEL, Klaus, SCHAUDT, Marco, SCHARN, Dirk, REIMER, Ulf, RICHTER, Uwe, HUMMEL, Gerd, REINEKE, Ulrich] Invalidenstr. 130 10115 Berlin;Porzellangasse 48/14 A-1090 Wien;Paulstr. 10 10557 Berlin;Wühlischstr. 57 10245 Berlin;Berliner Str. 89 13467 Berlin;Dunckerstr. 25 10437 Berlin;Alt-Koepenick 18 , WNG 0302 12555 Berlin;Pankstr. 12 13357 Berlin;Danckelmannstr. 53 14059 Berlin The present invention is related to a kinin B1 receptor antagonist for use in the treatment of a patient suffering from stricturing Crohn's Disease.

[LOCARDI, Elsa, DINKEL, Klaus, SCHAUDT, Marco, RICHTER, Uwe, SCHARN, Dirk, HUMMEL, Gerd, REINEKE, Ulrich, REIMER, Ulf] Invalidenstr. 130 10115 Berlin;Strelitzer Str. 25 10115 Berlin;Paulstr. 10 10557 Berlin;Wühlischstr. 57 10245 Berlin;Alt-Köpenick 18 12555 Berlin;Berliner Str. 89 13467 Berlin;Pankstrasse 12 13357 Berlin;Danckelmannstr. 53 14059 Berlin;Dunckerstr. 25 10437 Berlin Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.

[KOCH UWE, ZISCHINSKY GUNTHER, UNGER ANKE, NUSSBAUMER PETER, KLEBL BERT, CHOIDAS AXEL, DINKEL KLAUS, ENGEL JULIAN, DEGENHART CARSTEN, HUBER ROBERT, NAM KIYEAN, KIM JAESEUNG, SEO JEONGJEA, LEE SEUNG-JOO, JEON YEEJIN, AHN WONGYUN] DE;DE;DE;DE;DE;DE;DE;DE;DE;DE;DE;DE;KR;KR;KR;KR;KR;KR

[SAPOLSKY, Robert, M., MANLEY, Nathan, C., BROOKE, Sheila, DINKEL, Klaus, M., MUNHOZ, Carolina, D., RIEPEL, Angela, L., NICHOLAS, Andrea, C.] 1705 El Camino Real Palo Alto, CA 94306-1106;249 Edgewood Avenue San Francisco, CA 94117;74 Barns Court, No. 800 Stanford, CA 94305;1059 Lois Avenue Sunnyvale, CA 94087;Paulstr. 10 Berlin;2570 West Bayshore Rd. #5 Palo Alto, California 94303;1617 New Brunswick Avenue Sunnyvale, CA 94087;246 Casella Way San Ramon, CA 94582 The present invention provides methods for the delivery of therapeutic proteins to an area of inflammation and neuronal damage within the central nervous system (CNS). in this invention, immunocytes that can cross the blood brain barrier and access sites of CNS injury/inflammation, are genetically engineered to express and secrete a therapeutic protein of interest and are transplanted into a subject having a CNS injury. These genetically modified 'carrier immunocytes ' home to the site of a CNS lesion and secret the therapeutic agent, thereby ameliorating disease symptoms and pathology.

[Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel] DE Halle The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.

[FISCHER, Gunter, MALESEVIC, Miroslav, ERDMANN, Frank, KÜHLING, Jan, BUKRINSKY, Michael, CONSTANT, Stephanie, RÜHTER, Gerd, NUSSBAUMER, Peter, DINKEL, Klaus] Hofgartenstraße 8 80539 München;Otto-Hahn-Straße 15 44227 Dortmund;Otto-Kanning Straße 11 06120 Halle;Jägerplatz 11 06108 Halle;Burgstraße 42 06114 Halle;Gottesackerstraße 4 06108 Halle;8820 Brickyard Road Potomac, Maryland 20854;3013 Dower House Drive Herndon, Virginia 20171;Vierzigstücken 53 A 21129 Hamburg;Henriettenweg 37 44227 Dortmund;Am Bleckmannshof 40a 44799 Bochum The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.

[DINKEL, Markus, GÖTZ, Reinhold, PALM, Rainer, RUNKLER, Thomas, SCHMIDT, Thomas, VILLFORTH, Klaus] Wittelsbacherplatz 2 80333 München;Tanneckstr. 7 87745 Eppishausen;Theaterplatz 17 91054 Erlangen;Reisinger Str. 19 80337 München;Lüderitzstr. 14 81929 München;Keltenweg 32 86842 Türkheim;Mozartstr. 18 64342 Seeheim-Jugenheim The invention relates to a method for regulating whiteness for removal of printing ink in deinking installations, whereby printing ink particles in a fiber suspension are removed in a flotation cell (20) by means of gas bubbles. Said removal is carried out by removing the foam produced in a foam gutter (11), the amount of foam removed being adjusted. The method comprises the steps of measuring (24) a feed whiteness (ZW) of the fiber suspension added; determining an adjustable variable (SRN) as a function of the feed whiteness (ZW) and a predetermined desired value (SW) for an acceptor whiteness of the removed fiber suspension (26); adjusting the quantity of the removed foam subject to the adjustable variable (SRN).

[Robert Sapolsky, Nathan Manley, Sheila Brooke, Klaus Dinkel, Carolina Munhoz, Angela Riepel, Andrea Nicholas] US CA San Francisco The present invention provides methods for the delivery of therapeutic proteins to an area of inflammation and neuronal damage within the central nervous system (CNS). In this invention, immunocytes that can cross the blood brain barrier and access sites of CNS injury/inflammation, are genetically engineered to express and secrete a therapeutic protein of interest and are transplanted into a subject having a CNS injury. These genetically modified “carrier immunocytes” home to the site of a CNS lesion and secret the therapeutic agent, thereby ameliorating disease symptoms and pathology.

[DINKEL, Markus, MICKAL, Volkmar, RUNKLER, Thomas, SIEBER, Albrecht, VILLFORTH, Klaus] Wittelsbacherplatz 2 80333 München;Tanneckstr. 7 87745 Eppishausen;Kriegenbrunner Str. 10 91056 Erlangen;Lüderitzstr. 14 81929 München;Kornweg 4 91096 Möhrendorf;Mozartstr. 18 64342 Seeheim-Jugenheim

[Markus Dinkel, Volkmar Mickal, Thomas Runkler, Albrecht Sieber, Klaus Villforth] DE Eppishausen A method for the treatment of waste paper to produce a finished product in several process stages, comprises the steps of for at least one quality parameter, prescribing a set value for the finished product, wherein ahead of and/or following at least two of the process stages a value is determined by measurements of the at least one quality parameter, establishing the efficiency of a process stage with regard to the improvement of the at least one quality parameter in this process stage, and dynamically balancing in a process management system the individual process stages taking into account the overall efficiency of the process.